

Info Sheet for Technical description

No. 0027

Organization

* Mandatory fields

Name of Organization*	Kidswell Bio Corporation	
Address, City, States, Zip, Country*	3-8-3 Nihombashihoncho, Chio-ku, Tokyo, 103-0023, Japan	
URL	https://www.kidswellbio.com/en/	
Brief Descriptions of Organization* (Approx. 100 words)	Kidswell Bio Corporation, through wholly-owned subsidiary S-Quatre Corporation, promotes cell therapy (regenerative medicine) business focusing on Stem cells from human exfoliated deciduous teeth ("SHED"). The company is currently conducting a clinical study on Cerebral palsy, the business expected to form a rapid growth in the future.	
Contact address	Name*	Itsuki Kashin
	Department* / Position	Corporate Strategy Div. License & Alliance Dept.
	E-mail* / TEL	itsuki.kashin@kidswellbio.com

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines
- ☒ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B)
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

→ Please see **Sheet [A]**→ Please see **Sheet [B]**→ Please see **Sheet [C]**

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☒ Yes
- ☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☐ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	
☐ No	

Filled in by*

Date*

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No.A-0027-1

* Mandatoty fields

Title***Treatment of Celebral Palsy by Stem cells from human exfoliated deciduous teeth (SHED)****Development Phase***

- | | | |
|--|--|---|
| ☐ Basic Research | ☐ Drug Discovery | ☐ Pre-Clinical |
| ☒ Clinical Trial (Phase I) | ☐ Clinical Trial (Phase II) | ☐ Clinical Trial (Phase III) |
| ☐ Review | ☐ Others | |

Diesease Area*

- | | | |
|--|--|---|
| ☐ Cancer | ☒ Central nervous system | ☐ Ophthalmology |
| ☐ Musculoskeletal | ☐ Endocrine / Metabolism | ☐ Cardiovascular |
| ☐ Urogenital | ☐ Digestive organ | ☐ Blood |
| ☐ Infection | ☐ Dermatology | ☐ Immunity |
| ☐ Otolaryngology | ☐ Respiratory | ☐ Others |

Description*

Cerebral palsy (CP) has no established treatment specifically aimed at improving motor dysfunction, which is persistent and changeable symptoms caused by brain injuries occurred in the perinatal period.

S-Quatre (SQ), a wholly owned subsidiary of Kidswell Bio, has established a unique culture method to expand cell populations of SHED ("SQ-SHED") with high secretion of the factors related to nerve growth and angiogenesis contributing to the regeneration of nerves and bones.

SQ and Nagoya University found that systemic injection of SQ-SHED demonstrated a significant improvement of motor function and nerve regeneration in a model of CP and are now conducting a clinical study using autologous SHED. Interim results of the study will be disclosed in late 2025.

In parallel, SQ is promoting R&D to commercialize allogeneic SQ-SHED for CP treatment with Mochida Pharmaceutical in Japan market and preparing for the initiation of Phase 1b study. We are open for co-development or out-license of this program in the market outside Japan.

Filled in by*

S-Quatre Corporation

Date*

2-Sep-25